<DOC>
	<DOC>NCT00116844</DOC>
	<brief_summary>Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.</brief_summary>
	<brief_title>VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Herpesviridae Infections</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<criteria>In overall general good health. HSV2 (Herpes Simplex Virus2) seropositive at screening. Exclusion criteria: have active lesions consistent with genital herpes. previous history of symptomatic genital herpes. history of recurrent, undiagnosed symptoms consistent with genital herpes.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>viral shedding</keyword>
	<keyword>Recurrent</keyword>
	<keyword>herpes</keyword>
	<keyword>genital herpes</keyword>
</DOC>